Jasper Therapeutics Inc (NAS:JSPR) Stock News, Headlines & Updates
Jasper Therapeutics Inc Stock News from GuruFocus
- 1
Jul 09, 2025
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Marketwired • 8:00am
Jasper Therapeutics (JSPR) Restructures to Focus on Briquilimab Development | JSPR Stock News
GuruFocus News • 7:32am
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway | JSPR Stock News
GuruFocus News • 7:18am
Jul 08, 2025
JSPR: Jasper Therapeutics Faces Downgrade and Target Price Cut | JSPR Stock News
GuruFocus News • 1:34pm
JSPR: Jasper Therapeutics Faces Major Price Target Adjustment | JSPR Stock News
GuruFocus News • 9:34am
Evercore ISI Group Lowers Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News
GuruFocus News • 8:33am
Jul 07, 2025
Jasper Therapeutics (JSPR) Downgraded by William Blair | JSPR Stock News
GuruFocus News • 5:00pm
JSPR: HC Wainwright & Co. Adjusts Price Target for Jasper Therapeutics | JSPR Stock News
GuruFocus News • 4:31pm
JSPR: Jasper Therapeutics Receives Downgrade from Cantor Fitzgerald | JSPR Stock News
GuruFocus News • 4:01pm
JSPR: BTIG Lowers Price Target but Maintains Buy Rating | JSPR Stock News
GuruFocus News • 4:01pm
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
Marketwired • 7:00am
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria | JSPR Stock News
GuruFocus News • 6:45am
Jun 16, 2025
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | JSPR Stock News
GuruFocus News • 7:45pm
Jun 14, 2025
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
GlobeNewswire • 11:00am
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
Marketwired • 10:00am
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria | JSPR Stock News
GuruFocus News • 9:15am
Jun 03, 2025
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Marketwired • 8:00am
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | JSPR Stock News
GuruFocus News • 7:17am
May 15, 2025
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News
GuruFocus News • 1:35pm
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News
GuruFocus News • 6:53am
May 14, 2025
Jasper Therapeutics to Present at Upcoming Investor Conferences
Marketwired • 4:00pm
Jasper Therapeutics to Present at Upcoming Investor Conferences | JSPR Stock News
GuruFocus News • 3:51pm
May 13, 2025
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News
GuruFocus News • 11:35am
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News
GuruFocus News • 8:00am
May 12, 2025
Jasper (JSPR) Advances Briquilimab with Promising Trial Results | JSPR Stock News
GuruFocus News • 4:46pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news